<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7307801\results\search\testTrace\results.xml">
  <result pre="of Global Health jogh-10-010377 doi: 10.7189/jogh.10.010377 : Viewpoints Can early" exact="treatment" post="of patients with risk factors contribute to managing the"/>
  <result pre="To date there are still no drugs officially approved for" exact="treatment" post="of COVID-19. However, as already observed in SARS [6,7],"/>
  <result pre="as already observed in SARS [6,7], it appears that early" exact="treatment" post="with antiviral drugs could improve the natural history of"/>
  <result pre="COVID-19 and treating them with antivirals during early stages of" exact="infection" post="could be one strategy to manage the pandemic. COVID-19"/>
  <result pre="response of monocytes-macrophages [16]. Studies in animal models of SARS-CoV" exact="infection" post="have shown that intense virus replication associated with reduced"/>
  <result pre="with reduced production of INF I during early stages of" exact="infection" post="are associated with subsequent development of lung damage and"/>
  <result pre="Preliminary studies conducted on patients with COVID-19 show that early" exact="treatment" post="with antivirals can reduce patient mortality, while late-stage treatment"/>
  <result pre="early treatment with antivirals can reduce patient mortality, while late-stage" exact="treatment" post="does not improve survival [8,9]. The biphasic nature of"/>
  <result pre="the effectiveness of these treatments [8]. For individuals at risk," exact="treatment" post="with antivirals should therefore start at home as early"/>
  <result pre="after the onset of symptoms. Ideally, high-risk patients should start" exact="treatment" post="immediately after disease is confirmed by nasopharyngeal swabs. However,"/>
  <result pre="onset of symptoms, it may be ethically correct to start" exact="treatment" post="earlier in highly suspicious cases: patients at risk who"/>
  <result pre="Gerd Altmann from Pixabay. Antiviral drugs used for early home" exact="treatment" post="of patients at risk should meet the following requirements:"/>
  <result pre="antiviral drug that will be proven to be effective for" exact="treatment" post="of COVID-19, while maintaining the aforementioned characteristics of availability,"/>
  <result pre="safety, and ease of handling, could be considered for early" exact="treatment" post="of patients at risk. As with most strategies, starting"/>
  <result pre="of patients at risk. As with most strategies, starting early" exact="treatment" post="for large numbers of patients with risk factors would"/>
  <result pre="well documented history of use. The potential benefits of early" exact="treatment" post="for patients at risk of developing serious or lethal"/>
  <result pre="from other regions of the world become available. Early antiviral" exact="treatment" post="of symptomatic patients at risk could result in a"/>
  <result pre="based on the identification of subjects at risk and the" exact="treatment" post="with antivirals during early stages of disease. Funding: None."/>
  <result pre="Kong Med J. 2003;9:399-406.14660806 7ChuCMChengVCHungIFWongMMChanKHChanKSet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings.Thorax. 2004;59:252-6. 10.1136/thorax.2003.01265814985565"/>
  <result pre="Severe Covid-19.N Engl J Med. 2020;382:1787-99. 10.1056/NEJMoa200128232187464 9WuJLiWShiXChenZJiangBLiuJet al.Early antiviral" exact="treatment" post="contributes to alleviate the severity and improve the prognosis"/>
  <result pre="10.1038/d41573-020-00016-032127666 26VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread.Virol J. 2005;2:69. 10.1186/1743-422X-2-6916115318 27YaoXYeFZhangMCuiCHuangBNiuPet al.In vitro antiviral"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro.Cell Discov. 2020;6:16. 10.1038/s41421-020-0156-032194981 29ChoyKTWongAYKaewpreedeePSiaSFChenDHuiKPYet al.Remdesivir, lopinavir, emetine,"/>
  <result pre="10.1016/j.tmaid.2020.10166332289548 32MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on"/>
  <result pre="treatment of COVID-19: a multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on" exact="screening" post="for chloroquine and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838"/>
 </snippets>
</snippetsTree>
